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Editorial
Fatigue in rheumatoid arthritis
Fatigue is a common symptom in many rheumatic dis-
eases, including RA. However, until recently healthcare
professionals and researchers had not recognized its clin-
ical significance and its impact on patients’ lives. A turning
point came in 2002, at the Patient Perspective Workshop
of the OMERACT meeting, when patients highlighted the
importance of fatigue [1]. This led to the recommendation
by OMERACT in 2006 that fatigue is included as a core
outcome measure in clinical trials of RA treatments [2].
The process by which the rheumatology community has
come to recognize and focus on fatigue is an example of
the value of patient involvement in setting research prio-
rities. This awareness of fatigue as a patient priority has
led many researchers over the last decade to work on
better understanding the causes, assessment and man-
agement of fatigue.
Qualitative research has provided insight into the nature
of RA-related fatigue. Patients have described it as a com-
plex and multidimensional symptom that can be over-
whelming, unearned and unpredictable [3]. It can include
physical fatigue (e.g. levels of physical energy), cognitive
fatigue (e.g. concentration and clarity of thought), living
with fatigue (e.g. ability to carry out activities of daily
living and social activities) and emotional fatigue (e.g. feel-
ings of distress or upset) [4]. Quantitative research has
established that fatigue is highly prevalent in RA, with
levels similar to those in chronic fatigue syndrome [5].
In relation to impact, fatigue has been identified as the
consequence of RA that best differentiates between levels
of health-related quality of life [6]. Patients have reported
the negative effects of fatigue on their well-being, physical
activities, emotions, mood, relationships, and social and
family roles. From a societal perspective, fatigue is a sig-
nificant predictor of high health care costs, and is the main
reason for work disability and loss [7]. The detrimental
effects of fatigue are exacerbated by patients’ percep-
tions that the symptom is a challenge to manage and
that it is not routinely addressed in clinical practice. This
reluctance to discuss fatigue may reflect the lack of infor-
mation and available treatments. Consequently, fatigue is
widely recognized as important to patients, but how to
manage and improve the symptom remains a major
unmet need.
A challenge in providing support for RA-related fatigue
is that the causes are still unknown. Cross-sectional stu-
dies have found that fatigue is associated with pain se-
verity and psychosocial factors including depression, but
not disease activity [8]. Overall, the current evidence sug-
gests that fatigue is likely to be caused and maintained by
the complex interaction of clinical factors (e.g. inflamma-
tion, pain and disability), psychosocial issues (e.g. coping,
mood, beliefs and behaviours) and personal factors (e.g.
working, caring responsibilities and comorbidities) that
may vary both between and within individuals over time
[9]. This is reflected in evidence from systematic reviews
of non-pharmacological and pharmacological treatments
for fatigue, which have identified the potential benefit of
physical activity, psychosocial interventions and some
biologic DMARDs [10, 11]. The beneficial effect of biologic
DMARDs suggests that inflammation has a significant
pathobiological role, although fatigue does not completely
resolve. Experimental models have found that systemic
inflammation leads to increase in intracerebral IFN and
TNF-a activity [12]. Furthermore, in collagen-induced arth-
ritis, an animal-model of RA, the bloodbrain barrier is
porous to cytokines [13]. In patients with RA, a magnetic
resonance spectroscopy study suggested that systemic
inflammation may affect the neurochemical status of the
CNS with high levels of choline to creatine ratio [14].
Possibly due to the lack of clarity around causal path-
ways, there is an increasing focus on the self-manage-
ment of fatigue rather than the resolution or cure of the
symptom. Recent evidence includes a multicentre
randomized control trial using cognitive behavioural
approaches. This study found that the impact of fatigue
was reduced, with the positive effects maintained at 2
years [15]. Self-management interventions are typically
hypothesized to work through the therapeutic mechan-
isms of enhancing patients’ self-efficacy (the belief in
their ability to achieve a desired outcome or goal). This
is achieved by addressing patients’ illness beliefs, their
coping strategies and their acceptance of fatigue as a
symptom of their RA. In this study, the intervention
included the use of daily activity diaries and goal-setting
to promote a shift in beliefs and progressive adaptations
in how patients cope with fatigue, leading to better
knowledge, confidence and reactivation in everyday
activities.
Measurement is key to evaluating the usefulness of fa-
tigue interventions, whether the focus is on reducing se-
verity or managing the impact of the symptom. Although
OMERACT included fatigue as a core outcome measure in
RA, the lack of an RA-specific validated outcome measure
led to researchers adopting instruments developed for
other conditions to assess fatigue. However, this was
resolved in 2013 with the development, testing and pub-
lication of the Bristol Rheumatoid Arthritis Fatigue Scale
[16]. Designed in collaboration with patients, this multi-di-
mensional measure captures physical, cognitive, emo-
tional and social aspects of fatigue. In addition, three
numerical ratings scales enable researchers and health-
care professionals to measure fatigue severity, impact
and coping. As the factors driving and maintaining RA-
related fatigue are likely to vary between patients, insight
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into how individuals experience and perceive their fatigue
could be an important step in providing tailored support.
Patients have identified fatigue as a priority and a chal-
lenge to manage. In this supplement, authors have pro-
vided updates on the pathobiology, clinical assessment
and management of fatigue. Clarifying our current under-
standing and identifying the gaps in our knowledge is an
important step as we continue to look at ways of support-
ing patients with this common and difficult symptom.
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